Repare Therapeutics price target raised to $17 from $16 at Stifel

Stifel raised the firm’s price target on Repare Therapeutics to $17 from $16 and keeps a Buy rating on the shares ahead of initial phase 1 data for the combination of lunresertib and camonsertib that is expected at the AACR-NCI-EORTC meeting next month. The firm “leans with the bulls” and expects the combination to be substantially more active than either as a single agent and thinks synergistic efficacy may allow for lower, more tolerable doses of drug to be used, adding that it thinks the stock setup is favorable with two additional lunresertib combination updates on the horizon.